SEHK:2633

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Jacobson Pharma Corporation Limited, through its subsidiaries, manufactures and trades in generic drugs and proprietary medicines in Hong Kong, China, Macau, Singapore, and internationally. More Details


Snowflake Analysis

Undervalued with mediocre balance sheet.

Share Price & News

How has Jacobson Pharma's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 2633 is not significantly more volatile than the rest of Hong Kong stocks over the past 3 months, typically moving +/- 5% a week.

Volatility Over Time: 2633's weekly volatility (5%) has been stable over the past year.


Market Performance


7 Day Return

2.7%

2633

-0.8%

HK Pharmaceuticals

1.1%

HK Market


1 Year Return

-9.4%

2633

3.1%

HK Pharmaceuticals

8.2%

HK Market

Return vs Industry: 2633 underperformed the Hong Kong Pharmaceuticals industry which returned 3% over the past year.

Return vs Market: 2633 underperformed the Hong Kong Market which returned 7.6% over the past year.


Shareholder returns

2633IndustryMarket
7 Day2.7%-0.8%1.1%
30 Day1.8%-2.1%7.2%
90 Day-15.4%-11.2%5.2%
1 Year-6.1%-9.4%4.8%3.1%12.6%8.2%
3 Year-38.1%-43.1%-4.5%-10.0%0.4%-10.0%
5 Yearn/a28.9%18.7%30.6%8.5%

Long-Term Price Volatility Vs. Market

How volatile is Jacobson Pharma's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Jacobson Pharma undervalued compared to its fair value and its price relative to the market?

30.9%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: 2633 (HK$1.15) is trading below our estimate of fair value (HK$1.66)

Significantly Below Fair Value: 2633 is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: 2633's PE Ratio (10.7x) is in line with the HK Pharmaceuticals industry average.

PE vs Market: 2633 is good value based on its PE Ratio (10.7x) compared to the Hong Kong market (11.2x).


Price to Earnings Growth Ratio

PEG Ratio: 2633 is good value based on its PEG Ratio (0.9x)


Price to Book Ratio

PB vs Industry: 2633 is good value based on its PB Ratio (0.9x) compared to the HK Pharmaceuticals industry average (1.1x).


Next Steps

Future Growth

How is Jacobson Pharma forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

12.1%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 2633's forecast earnings growth (12.1% per year) is above the savings rate (1.6%).

Earnings vs Market: 2633's earnings (12.1% per year) are forecast to grow slower than the Hong Kong market (21.9% per year).

High Growth Earnings: 2633's earnings are forecast to grow, but not significantly.

Revenue vs Market: 2633's revenue (7% per year) is forecast to grow slower than the Hong Kong market (13.7% per year).

High Growth Revenue: 2633's revenue (7% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: 2633's Return on Equity is forecast to be low in 3 years time (11.6%).


Next Steps

Past Performance

How has Jacobson Pharma performed over the past 5 years?

16.5%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 2633 has high quality earnings.

Growing Profit Margin: 2633's current net profit margins (13.6%) are lower than last year (16.6%).


Past Earnings Growth Analysis

Earnings Trend: 2633's earnings have grown by 16.5% per year over the past 5 years.

Accelerating Growth: 2633's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 2633 had negative earnings growth (-12.9%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-11.9%).


Return on Equity

High ROE: 2633's Return on Equity (8.3%) is considered low.


Next Steps

Financial Health

How is Jacobson Pharma's financial position?


Financial Position Analysis

Short Term Liabilities: 2633's short term assets (HK$1.2B) exceed its short term liabilities (HK$727.4M).

Long Term Liabilities: 2633's short term assets (HK$1.2B) do not cover its long term liabilities (HK$1.2B).


Debt to Equity History and Analysis

Debt Level: 2633's debt to equity ratio (59.6%) is considered high.

Reducing Debt: 2633's debt to equity ratio has increased from 52.5% to 59.6% over the past 5 years.

Debt Coverage: 2633's debt is well covered by operating cash flow (23.3%).

Interest Coverage: 2633's interest payments on its debt are well covered by EBIT (6.1x coverage).


Balance Sheet


Next Steps

Dividend

What is Jacobson Pharma current dividend yield, its reliability and sustainability?

3.91%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: 2633's dividend (3.91%) is higher than the bottom 25% of dividend payers in the Hong Kong market (2.23%).

High Dividend: 2633's dividend (3.91%) is low compared to the top 25% of dividend payers in the Hong Kong market (6.58%).


Stability and Growth of Payments

Stable Dividend: Whilst dividend payments have been stable, 2633 has been paying a dividend for less than 10 years.

Growing Dividend: 2633's dividend payments have increased, but the company has only paid a dividend for 4 years.


Current Payout to Shareholders

Dividend Coverage: With its reasonably low payout ratio (41.7%), 2633's dividend payments are well covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.6yrs

Average board tenure


CEO

Derek Sum (57 yo)

no data

Tenure

HK$4,958,000

Compensation

Mr. Sum Kwong Yip, also known as Derek, serves as Chairman and Chief Executive Officer of Jacobson Pharma Corporation Limited. Mr. Sum has been Executive Director of Jacobson Pharma Corporation Limited sin...


CEO Compensation Analysis

Compensation vs Market: Derek's total compensation ($USD639.66K) is above average for companies of similar size in the Hong Kong market ($USD292.59K).

Compensation vs Earnings: Derek's compensation has been consistent with company performance over the past year.


Board Members

NamePositionTenureCompensationOwnership
Kwong Yip Sum
Chairmanno dataHK$4.96m58.89%
HK$ 1.3b
Yue Wai Pun
VP of Administration & Executive Director3.75yrsHK$1.46m0.11%
HK$ 2.5m
Chun Leung Yim
Company Secretary & Executive Director4.58yrsHK$3.58m1.54%
HK$ 34.3m
Sing Kwong Lam
Non-Executive Director4.58yrsHK$211.00kno data
Chun Man Young
Independent Non-Executive Director4.25yrsHK$220.00kno data
Kwok Chow
Member of Scientific Advisory Committee4.58yrsno datano data
Wai Lee
Member of Scientific Advisory Committee4.58yrsno datano data
Hoi Yee Tong
Member of Scientific Advisory Committee4.58yrsno datano data
Chi Kei Wong
Independent Non-Executive Director & Member of Scientific Advisory Committee2.92yrsHK$220.00kno data
Kwing Tong Lam
Independent Non-Executive Director4.25yrsHK$220.00k0.024%
HK$ 540.5k

4.6yrs

Average Tenure

57yo

Average Age

Experienced Board: 2633's board of directors are considered experienced (4.6 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Jacobson Pharma Corporation Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Jacobson Pharma Corporation Limited
  • Ticker: 2633
  • Exchange: SEHK
  • Founded: 2016
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: HK$2.224b
  • Shares outstanding: 1.93b
  • Website: https://www.jacobsonpharma.com

Number of Employees


Location

  • Jacobson Pharma Corporation Limited
  • Tower 1, Millennium City
  • 23rd Floor
  • Kwun Tong
  • Kowloon
  • Hong Kong

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
2633SEHK (The Stock Exchange of Hong Kong Ltd.)YesOrdinary SharesHKHKDSep 2016

Biography

Jacobson Pharma Corporation Limited, through its subsidiaries, manufactures and trades in generic drugs and proprietary medicines in Hong Kong, China, Macau, Singapore, and internationally. The company off...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/11/26 10:03
End of Day Share Price2020/11/26 00:00
Earnings2020/03/31
Annual Earnings2020/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.